Description
Xiamen Amoytop Biotech Co., Ltd. is a leading manufacturer of recombinant bio-pharmaceutical products in China, operating under cGMP (current Good Manufacturing Practice) standards. The company produces a range of biologics, including Molgramostim, Filgrastim, Oprelvekin, and Peginterferon alfa 2b, which are marketed domestically and exported to various countries. In addition to its pharmaceutical offerings, Xiamen Amoytop supplies bio-reagents for laboratory and research applications, such as Interleukin-4, TNF-alfa, IFN-gamma, IL-15, and SCF. Furthermore, the company is at the forefront of developing innovative drug delivery technologies, including their Y-shaped branch PEG Drug Delivery Technology for Pegfilgrastim, Pegsomatropin, and Peg-EPO. As the first and largest company to launch domestic Molgramostim in China, Xiamen Amoytop serves as a reference standard supplier to national institutes.
Services include:
– APIs (Active Pharmaceutical Ingredients)
– Biologics
– Contract Manufacturing (CMO/CDMO)
– Contract Research Organisation (CRO)
– Contract Services
– Consumer Goods
– Distributor
Xiamen Amoytop Biotech Co., Ltd. is dedicated to advancing biopharmaceutical research and production, ensuring high-quality products and services that meet the needs of the pharmaceutical industry. For more information, please visit amoytop.com.
Capabilities
Contact Information
Related Listings

CDMO Live Europe 2026
Experience the future of external manufacturing at CDMO Live, Rotterdam.
19-21st May 2026

External Manufacturing Leaders Boston 2026
Exclusive event for senior external manufacturing leaders. Boston, January 2026











